As previously mentioned, since TP53 mutations are rare in melanoma, activation of wtp53, by releasing it from the prominent MDM2 inhibitory effect, is considered a promising strategy in melanoma therapy [7,17,35]. The gene discussed is MDM2; the disease is melanoma.